Kezar Life Sciences Inc (NASDAQ:KZR)’s share price was up 7.5% on Friday . The company traded as high as $7.95 and last traded at $7.71. Approximately 642,139 shares traded hands during mid-day trading, an increase of 518% from the average daily volume of 103,883 shares. The stock had previously closed at $7.17.
A number of analysts have weighed in on KZR shares. Zacks Investment Research raised shares of Kezar Life Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Saturday, March 16th. William Blair reissued an “outperform” rating on shares of Kezar Life Sciences in a report on Tuesday, March 12th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Kezar Life Sciences has an average rating of “Buy” and an average target price of $24.33.
The company has a debt-to-equity ratio of 0.06, a quick ratio of 21.81 and a current ratio of 21.81. The stock’s fifty day simple moving average is $12.56.
Large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA lifted its holdings in shares of Kezar Life Sciences by 131,900.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,640 shares of the company’s stock worth $47,000 after acquiring an additional 2,638 shares during the period. BB Biotech AG bought a new position in shares of Kezar Life Sciences during the 4th quarter worth about $19,315,000. BlackRock Inc. lifted its holdings in shares of Kezar Life Sciences by 1.9% during the 4th quarter. BlackRock Inc. now owns 245,932 shares of the company’s stock worth $5,804,000 after acquiring an additional 4,486 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Kezar Life Sciences by 126.7% during the 4th quarter. Geode Capital Management LLC now owns 58,046 shares of the company’s stock worth $1,369,000 after acquiring an additional 32,441 shares during the period. Finally, Spark Investment Management LLC lifted its holdings in shares of Kezar Life Sciences by 125.3% during the 1st quarter. Spark Investment Management LLC now owns 21,200 shares of the company’s stock worth $376,000 after acquiring an additional 11,790 shares during the period. 51.88% of the stock is owned by institutional investors.
About Kezar Life Sciences (NASDAQ:KZR)
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.
Featured Article: What impact do institutional investors have on markets?
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.